Sucralfate dose
Pro Research Analysisby 
Searched over 200M research papers for "sucralfate dose"
Sucralfate Dosage: Efficacy and Applications
Twice-Daily Sucralfate for Duodenal Ulcer Healing
Efficacy of 2 g Twice Daily (B.I.D.) Dosage
Research has demonstrated that a 2 g twice-daily (B.I.D.) dosage of sucralfate is significantly effective in healing acute duodenal ulcers. In two multicenter trials, patients receiving 2 g B.I.D. showed higher healing rates compared to those on placebo or a single bedtime dose (H.S.) of sucralfate. Specifically, in an eight-week trial, 76% of patients on the B.I.D. regimen were healed by the end of the study, compared to 57% on the H.S. regimen and 39% on placebo . A four-week trial also showed superior healing rates for the B.I.D. group at both two and four weeks .
Sucralfate in Pediatric Oral Ulcers
Dosage and Efficacy in Children
A study investigating the use of sucralfate in children with infectious oral ulcers found that a dosage of 20 mg/kg per dose up to 1 g, administered alongside oral analgesics, did not significantly improve oral fluid intake compared to placebo. The median intake was similar between the sucralfate and placebo groups, and secondary outcomes such as repeat emergency visits and length of stay showed no significant differences .
Sucralfate for Radiation-Induced Side Effects in Head and Neck Cancer
Dosage and Efficacy in Reducing Radiation-Induced Complications
In patients undergoing radiotherapy for head and neck cancers, a dosage of 1 g six times daily was tested to see if it could reduce acute radiation-induced side effects. The study found no significant differences in subjective intolerance, mucositis, dysphagia, dermatitis, or nausea between the sucralfate and placebo groups. Therefore, the prophylactic use of sucralfate in this context is not recommended .
Maintenance Therapy for Gastric Ulcer Recurrence
Dosage and Long-Term Efficacy
A maintenance dosage of 1 g in the morning and 2 g at night (totaling 3 g per day) has been shown to significantly reduce the recurrence rate of gastric ulcers. In a six-month trial, only 16% of patients on sucralfate experienced ulcer recurrence compared to 70% on placebo, with most recurrences occurring within the first 12 weeks .
Comparative Studies with Other Medications
Comparison with Cimetidine
A study comparing sucralfate (2 g twice daily) with cimetidine (400 mg twice daily) for gastric ulcer healing found no significant difference in efficacy between the two treatments. Both medications showed similar healing rates at four, eight, and twelve weeks .
Sucralfate for NSAID-Induced Gastrointestinal Symptoms
Dosage and Efficacy in Symptom Relief
For patients experiencing gastrointestinal symptoms and mucosal damage due to nonsteroidal anti-inflammatory drugs (NSAIDs), a dosage of 1 g four times daily was effective in reducing both symptom frequency and intensity. Long-term use of sucralfate continued to show improvement in gastrointestinal symptoms and mucosal lesion scores .
Alternative Dosage Schedules
Comparison of 2 g Twice Daily vs. 1 g Four Times Daily
A study comparing the conventional 1 g four times daily regimen with a 2 g twice daily regimen for duodenal ulcer healing found both schedules to be equally effective. After four weeks, 79% of patients on the 2 g twice daily regimen had healed ulcers compared to 72% on the 1 g four times daily regimen .
Conclusion
Sucralfate is a versatile medication effective in treating various gastrointestinal conditions, particularly duodenal and gastric ulcers. The twice-daily 2 g dosage has been shown to be as effective as the more frequent 1 g four times daily regimen, offering a more convenient option for patients. However, its efficacy in other conditions, such as radiation-induced side effects and pediatric oral ulcers, appears limited. Further research may help refine its applications and optimize dosing strategies.
Sources and full results
Most relevant research papers on this topic
Sucralfate as an Adjunct to Analgesia to Improve Oral Intake in Children With Infectious Oral Ulcers: A Randomized, Double-Blind, Placebo-Controlled Trial.
Sucralfate as an adjunct to oral analgesics did not significantly improve oral intake in children with acute oral infectious ulcers.
Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial.
Oral sucralfate does not reduce acute radiation-induced side-effects in head and neck cancer patients treated by radiotherapy, and its prophylactic use is not recommended.
DOI